Craig England, the founding partner of England & Company, is an investment banker with over 30 years of experience in M&A advisory, financial restructuring services, and private finance.
Prior to forming England & Company, Mr. England was a Principal in Legg Mason’s Investment Banking Group where he concentrated on software and financial services companies. Prior to Legg Mason, he was a Vice President with Alex. Brown & Sons in New York and Baltimore where he led the firm’s Asset Securitization Group. Additionally, Mr. England served as a Vice President and private placement specialist at New York City-based Hunter, Keith, Marshall & Co., and Corporate Finance Director for ICON Capital Corp. He began his career as a corporate lender in the financial institutions groups of the Irving Trust Company (now the Bank of New York) and the Canadian Imperial Bank of Commerce.
Mr. England earned his BA from the Johns Hopkins University, completed studies in International Economics at the Universite Libre de Bruxelles and received his MBA in Finance from the Stern School of Business at New York University.
Andy Cowherd has over 25 years of investment banking and private equity investing experience focused on the healthcare sector. In these roles, he has completed a wide range of M&A and strategic advisory assignments, as well as numerous private and public financings, as both an advisor and principal.
Prior to joining England & Company in 2015, Mr. Cowherd was a Managing Director of Healthcare Investment Banking at Mesirow Financial. He also served as a Managing Director at Peter J. Solomon Company, Salomon Brothers, and BT Securities / Bankers Trust Co. In addition, Mr. Cowherd was a founding member and General Partner of Atlantic Medical Capital, LP, a private equity firm focused on the healthcare industry.
Mr. Cowherd earned his AB from Princeton University and his MBA from the Stanford University Graduate School of Business.
Kian Kiat Tan has over 25 years of experience in investment banking, strategic consulting, and corporate multinationals. Mr. Tan has been involved in various fundraising, mergers and acquisitions, capital markets (Equity and Debt), and corporate restructuring transactions. He has also advised many public and private companies and financial sponsors on strategic transactions. In addition, he has been part of the senior management team within a multinational corporation focused on mergers and acquisitions and business development opportunities.
Prior to joining England & Company, Mr. Tan was an Executive Director with a UK residential real estate development company where he led the fundraising effort targeting institutional and family office investors. Previously, Mr. Tan worked at Nippon Paint, the large Japanese paint and coatings company, where he was the Head of Mergers and Acquisitions. Prior to Nippon Paint, Mr. Tan was a Director and Head of Southeast Asia for Avista Houlihan Lokey based in Singapore. Mr. Tan has in-depth experience with broad international exposure in mergers and acquisitions, fundraising, and corporate development strategy. He has successfully completed transactions valued at over $8 billion globally. Mr. Tan began his career in the UK as a Chartered Accountant and worked across Asia in a professional services firm, investment bank, and multinational corporation, focusing on the Real Estate, Consumer, TMT, Financial Services, Pharmaceutical & Healthcare, and Industrial sectors.
Mr. Tan is a Fellow Member of the Association of Chartered Certified Accountants (UK) (FCCA) and holds a degree (BA Hons) in Accountancy from De Montfort University. He received an MBA from the Chicago Booth School of Business, and a Postgraduate Degree Masters level, PGDip in Global Business from Oxford University’s Saïd Business school.
Paul Teitelbaum has over 25 years of healthcare investment banking, corporate development, and management experience, with a particular focus on medical technology and life sciences. He has completed numerous M&A, financing, and strategic partnership transactions for private and public companies.
Prior to joining England & Company in 2015, Mr. Teitelbaum was Managing Director of the Healthcare Investment Banking Group at Mesirow Financial. He also served as a Managing Director of Healthcare Investment Banking at Landmark Ventures, and as a healthcare investment banker at Robertson Stephens and Burnham Securities. Previously, Mr. Teitelbaum held corporate development and disease management roles at Schering-Plough (now Merck & Co., Inc.) and Wyeth-Lederle (now Pfizer, Inc.).
Mr. Teitelbaum received his BA in Biology summa cum laude from the University of Pennsylvania and his MBA in Finance from the Wharton School of the University of Pennsylvania.
Scott Cousino has over 30 years of investment banking experience primarily focused on the healthcare sector where he has completed a wide range of M&A, strategic advisory, and capital markets transactions.
Prior to joining England & Company in 2013, Mr. Cousino was a Managing Director at Stifel Nicolaus Weisel, where he had served as Head of its Healthcare Investment Banking Group. He also served as a Managing Director and Head of Healthcare Investment Banking at Legg Mason prior to its acquisition by Stifel in 2005. In addition, Mr. Cousino served as Chairman of the Fairness Opinion Committee at Stifel and Legg Mason for over ten years.
Mr. Cousino earned his BBA and MBA in Finance from the College of William and Mary. He has been active on numerous non-profit boards and currently serves on the Finance Committee of the Y of Central Maryland.